Cell and Gene Therapy
Cell and gene therapy (CGT) represents a revolutionary shift in how we treat, manage, and potentially cure a wide range of diseases—from rare genetic disorders to cancer, and beyond. By targeting the root causes of disease at the molecular level, CGTs offer hope where traditional therapies have fallen short.
Cell and Gene Therapy ELISA refers to a specialized application of ELISA technology used to:
- Quantify transgene expression (e.g., AAV-delivered proteins, CAR-T markers)
- Monitor host immune response (e.g., cytokine release, anti-drug antibodies)
- Detect impurities or residuals (e.g., host cell proteins, plasmid DNA)
- Ensure product potency and consistency
These assays are designed to meet the unique challenges of CGT workflows, from early-stage discovery to late-stage clinical trials and commercial manufacturing.
Applications Across Therapeutic Areas:
| Area | Example Therapies |
|---|---|
| Oncology | CAR-T, TCR-T cell therapies for leukemia and solid tumors |
| Genetic Disorders | AAV-based gene therapy for spinal muscular atrophy (SMA), hemophilia |
| Ophthalmology | Gene therapies for inherited retinal diseases |
| Neurology | Experimental treatments for ALS, Parkinson’s, and more |
| Regenerative Medicine | Stem cell therapies for heart failure, osteoarthritis |
Krishgen offers a wide variety of ELISAs for estimation of CAR-T Target Proteins: